Nimrata Hunt
Known title: DirectorCIK: 0001800619
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Veeva Gains Investor Attention Amid R&D Growth and AI Focus. Veeva Systems is drawing investor interest as analysts note strong R&D growth and a positive outlook. The company has secured a major research partner that now uses its software as the default clinical platform, and a recent IQVIA deal expands its market reach. Large institutional investors are also increasing exposure to Veeva as part of an AI software play.
Transaction History
| IDXX | ▼ Sell | Open Market | 1,758 | $1.1M | 3/3/2026 | View on chart |
| IDXX | ▼ Sell | Open Market | 2,693 | $1.8M | 2/26/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 1,508 | $0 | 2/14/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 367 | $0 | 2/14/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 204 | $0 | 2/14/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 207 | $0 | 2/14/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 301 | $0 | 2/14/2026 | View on chart |
| IDXX | ▼ Sell | Tax Withholding | 1,154 | $726K | 2/14/2026 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 7,125 | $2.1M | 11/7/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 5,405 | $2.7M | 11/7/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 5,114 | $3.6M | 11/7/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 1,465 | $1.0M | 11/7/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 1,468 | $1.0M | 11/7/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 1,378 | $972K | 11/7/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 560 | $100K | 8/12/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 483 | $100K | 8/12/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 183 | $100K | 8/12/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 1,200 | $788K | 8/11/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 1,218 | $768K | 8/6/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 1,218 | $172K | 8/6/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 2,907 | $1.8M | 8/6/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 5,711 | $1.2M | 8/6/2025 | View on chart |
| IDXX | ▼ Sell | Open Market | 3,018 | $1.9M | 8/6/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 5,865 | $1.0M | 8/6/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 6/1/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 342 | $0 | 3/1/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 207 | $0 | 2/14/2025 | View on chart |
| IDXX | ▼ Sell | Tax Withholding | 268 | $119K | 2/14/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 160 | $0 | 2/14/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 301 | $0 | 2/14/2025 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 204 | $0 | 2/14/2025 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 12/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 343 | $0 | 9/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 6/1/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 3/1/2024 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 126 | $0 | 2/14/2024 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 173 | $0 | 2/14/2024 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 161 | $0 | 2/14/2024 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 204 | $0 | 2/14/2024 | View on chart |
| IDXX | ▼ Sell | Tax Withholding | 263 | $147K | 2/14/2024 | View on chart |
| IDXX | ▲ Buy | Grant | 208 | $0 | 2/14/2024 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 303 | $0 | 12/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 302 | $0 | 9/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 300 | $0 | 6/1/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 299 | $0 | 3/1/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 126 | $0 | 2/14/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 127 | $0 | 2/14/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 173 | $0 | 2/14/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 161 | $0 | 2/14/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 204 | $0 | 2/14/2023 | View on chart |
| IDXX | ▼ Sell | Tax Withholding | 239 | $120K | 2/14/2023 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 706 | $100K | 2/9/2023 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 300 | $0 | 12/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 300 | $0 | 9/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 254 | $0 | 6/1/2022 | View on chart |
| VEEV | ▲ Buy | Option Exercise | 169 | $0 | 3/1/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 127 | $0 | 2/14/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 173 | $0 | 2/14/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 161 | $0 | 2/14/2022 | View on chart |
| IDXX | ▼ Sell | Tax Withholding | 204 | $103K | 2/14/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 88 | $0 | 2/14/2022 | View on chart |
| IDXX | ▲ Buy | Option Exercise | 126 | $0 | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
KeyBanc initiates IDEXX coverage with Sector Weight rating
KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.
KeyBanc initiates IDEXX coverage with Sector Weight rating. KeyBanc has started covering IDEXX Laboratories, assigning it a Sector Weight rating. This move adds to analyst attention as investors look ahead to the company's upcoming Q3 2026 earnings report. The stock is currently trading near its 52-week high, reflecting strong recent performance.